Optimization of Autologous Serum Eye Drops: Study of Filtration on Active Molecule Concentration in Patients With Dry Eye Disease (IFilCoSA)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Differences in concentrations of active molecules
研究概览
简要总结
Dry eye disease accounts for nearly 25% of ophthalmology consultations, making it a commonly encountered condition. When conventional treatments fail autologous serum in the form of eye drops, have been proposed as a therapeutic option. With the aim of standardizing the preparation of autologous serum eye drops in France, the main objective is to describe the absolute and relative differences (before and after filtration) in the concentrations of active molecules in the autologous serum of patients suffering from severe dry eye disease.
详细描述
Sterility, which is a mandatory specification for eye drops, represents a critcial step in their manufacturing process. A review of the literature shows that 62% of articles (n=42) addressing the manufacturing process of autologous serum eye drops do not include a filtration step. Among those reporting filtration, slightly over 9% do not specify the porosity used, 4.8% use filters with a porosity of 0.45µm (clarifying filtration), and slightly over 23% use filters with a porosity ≤ 0.22µm ( sterilizing filtration). Several molecules present in autologous serum have been described in the literature, but five are widely recognized as the main contributors to its therapeutic efficacy: EGF, TGF-ß, IGF-1, Fibronectin, and Vitamin A. The impact of sterilizing filtration on the concentrations of thesemolecules in the final serum used for eye drop preparation therefore warrants investigation. Ten patients will be recruited from the ophthalmology department. A pre-screening phase will be conducted to identify eligible patients and propose the study participation. A dedicated follow-up consultation will be organized for inclusion. Serological tests will be performed on the blood samples of eligible patients. Only patients with negative serology for HIV, HBV, HCV and Treponema pallidum will be included. Their serum will be processed, at the Pharmaceutical Preparations Unit, to produce multiple aliquots following coagulation and centrifugation, with subsequentfiltration using 2 different filter materials, with 2 different porosities, or no filtration. These aliquots will then be sent to the Biochemistry department and Pharmacology department for the quantitative analysis of molecules of interest.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
盲法说明
The biological analyses are carried out blindly
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adult patients
- •patients covered by health insurance
- •patients managed by the Ophtalmology Department of the University Hospital of Limoges
- •patients diagnosed with dry eyes syndrome, who have not responded to conventionnal treatments
- •free, informed, written and signed consent
排除标准
- •person incapable of consent
- •legal guardianship or wardship
- •patient who does not wish to know the results of serological tests
- •Secondary exclusion criteria:
- •- a positive serology for at least of of the following agents (HIV, HCV, HBV or syphilis)
研究组 & 干预措施
Serum
analyse sera
干预措施: Serum dosage of TGF-β, IGF-1, EGF, Fibronectin and Vitamin A (Biological)
结局指标
主要结局
Differences in concentrations of active molecules
时间窗: At the inclusion
Absolute and relative differences in concentrations, before/after filtration (clarifying or sterilizing, and using polyethersulfone or cellulose acetate), of the following active molecules: EGF, TGF-ß, IGF-1, Fibronectin, and Vitamin A.
次要结局
- Concentration of active molecules(At the inclusion)
- Physiological parameters of patients to graduate chronical dry eye disease(At the inclusion)
- OSDI quality of life questionnary(At the inclusion)
- Description of the concentrations of active molecules in the serum before filtration.(At the inclusion)
- Description of the proposed patient pathway and manufacturing process.(From the inclusion to the end of results 7 days later)
